# RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

Study · id `cardio:ct-nct07203521` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07203521](<https://clinicaltrials.gov/study/NCT07203521>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07203521

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 194 participants.

## Technical summary

Registry record NCT07203521. Randomized; single masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 194 participants (planned count; ClinicalTrials.gov record NCT07203521, source copy `cardio:ctgov-nct07203521-2025-10-02`, retrieved 2026-10-26)
- Planned start: 2025-11-01 (anticipated) (ClinicalTrials.gov record NCT07203521, source copy `cardio:ctgov-nct07203521-2025-10-02`, retrieved 2026-10-26)
- Primary completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT07203521, source copy `cardio:ctgov-nct07203521-2025-10-02`, retrieved 2026-10-26)
- Completion: 2026-10-07 (anticipated) (ClinicalTrials.gov record NCT07203521, source copy `cardio:ctgov-nct07203521-2025-10-02`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07203521-2025-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
- Condition: Acute Large Hemispheric Infarction Stroke
- Condition: Transcranial Bone Marrow Injection
- Condition: RK-4
- Condition: Acute Ischemic Stroke
- Intervention (Drug): RK-4 injection
- Intervention (Other): conventional treatment
- Lead sponsor: Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 78b7f1e1ca7e7fa34dd1da453fdb8134f721eab1c363119b564847e956b46d24
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
